More recently, in a clinical trial, promising results were observed in age-related macular degeneration neovascularization by using VEGF-C/VEGF-D inhibitor OPT-302 along with VEGF-A inhibitor ranibizumab. The gene discussed is VEGFD; the disease is age-related macular degeneration.